Parallax Volatility Advisers
RVNC

Parallax Volatility Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Parallax Volatility Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,000
Closed -$633K – 2693
2023
Q2 		$633K Buy
+25,000
New +$779K ﹤0.01% 1568
2018
Q1 		– Sell
-42,600
Closed -$1.52M – 4533
2017
Q4 		$1.52M Buy
+42,600
New +$1.22M ﹤0.01% 1022

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's RVNC Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 10,085 shares — an estimated $194K sold.

Parallax Volatility Advisers first reported a position in RVNC in Q4 2017 and held it in 4 quarters. The position peaked at $1.24M in Q4 2017. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Parallax Volatility Advisers reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 10,085 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $194K.
  • Parallax Volatility Advisers first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Revance Therapeutics, Inc. position peaked at $1.24M in Q4 2017.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.